Fda

Patrizia Cavazzoni's FDA to Pfizer Move Epitomizes Regulatory Capture

2025-01-15 00:00:00 +0000 UTC | Importance: 9/10

Dr. Patrizia Cavazzoni, former head of the FDA’s Center for Drug Evaluation and Research (CDER), immediately transitioned to Pfizer as chief medical officer, reigniting intense debate about the pharmaceutical industry’s regulatory influence and the problematic ‘revolving …

Patrizia Cavazzoni FDA Pfizer Robert F. Kennedy Jr. Center for Drug Evaluation and Research +2 more regulatory-capture pharmaceutical-industry fda revolving-door institutional-corruption +2 more

FDA Commissioner Califf's Pharmaceutical Industry Revolving Door Scrutinized

2024-09-20 00:00:00 +0000 UTC | Importance: 8/10

FDA Commissioner Robert Califf faces ongoing criticism for his extensive pharmaceutical industry ties. Having received over $8 million from drug companies and worked as a consultant for major pharmaceutical firms, Califf pledged to extend post-employment restrictions from 2 to 4 years to mitigate …

Robert Califf FDA Verily Life Sciences Joe Manchin Bernie Sanders regulatory-capture pharmaceutical-industry fda corporate-influence government-ethics

Former FDA Commissioner Stephen Hahn Joins Moderna Backer Flagship Pioneering

2021-10-01 00:00:00 +0000 UTC | Importance: 8/10

Former FDA Commissioner Stephen Hahn, who led the agency during the Emergency Use Authorization of Moderna’s COVID-19 vaccines, took an executive-level position as Chief Medical Officer with Flagship Pioneering, the venture capital firm that launched Moderna. This transition occurred six …

Stephen Hahn Flagship Pioneering Moderna Food and Drug Administration Noubar Afeyan +1 more regulatory-capture pharmaceutical-industry revolving-door covid-19 fda

Former FDA Commissioner Scott Gottlieb Joins Pfizer Board After 3-Month Gap

2019-06-27 00:00:00 +0000 UTC | Importance: 8/10

Pfizer announced that Dr. Scott Gottlieb, who served as FDA Commissioner from May 2017 to April 2019, would join the pharmaceutical giant’s board of directors as an independent member. The appointment came just 85 days after Gottlieb resigned from the FDA, raising immediate concerns about …

Dr. Scott Gottlieb FDA Pfizer Senator Elizabeth Warren regulatory-capture fda pharmaceuticals revolving-door board-appointment +1 more

FDA Commissioner Scott Gottlieb Joins Pfizer Board After Leaving Agency

2019-06-27 00:00:00 +0000 UTC | Importance: 8/10

Scott Gottlieb, former FDA Commissioner, joined Pfizer’s board of directors on June 27, 2019, just 85 days after leaving the FDA. The move sparked significant criticism about the ‘revolving door’ between government regulatory agencies and pharmaceutical companies. Gottlieb will …

Scott Gottlieb Elizabeth Warren Pfizer Board of Directors Food and Drug Administration regulatory-capture pharmaceutical-industry revolving-door fda conflict-of-interest

FDA Statistician Joan Buenconsejo Joins AstraZeneca After Overseeing Company Drug Reviews

2014-06-01 00:00:00 +0000 UTC | Importance: 7/10

Joan Buenconsejo, who led FDA analysis of medical statistics for drug reviews including AstraZeneca products in 2012-2013, joined AstraZeneca as a director and biometrics team leader in June 2014. This transition exemplifies the systemic ‘revolving door’ problem in pharmaceutical …

Joan Buenconsejo FDA AstraZeneca Center for Drug Evaluation and Research regulatory-capture pharmaceutical-industry fda revolving-door conflict-of-interest

FDA Arthritis Drug Reviewer Jeffrey Siegel Joins Genentech After Approving Company Tocilizumab

2010-12-15 00:00:00 +0000 UTC | Importance: 7/10

Jeffrey Siegel, an FDA staff member specializing in arthritis drug reviews, oversaw the 2010 approval of Genentech tocilizumab (Actemra) for arthritis treatment. Within months of the approval, Siegel left the FDA to join Genentech and its parent company Roche as director of the division that …

Jeffrey Siegel FDA Genentech Roche Actemra regulatory-capture pharmaceutical-industry fda revolving-door drug-approval

FDA Whistleblower David Graham Testifies on Vioxx Cover-up Before Senate

2004-11-18 00:00:00 +0000 UTC | Importance: 9/10

FDA epidemiologist Dr. David Graham delivered explosive testimony before the U.S. Senate Finance Committee, declaring that ’the FDA, as currently configured, is incapable of protecting America against another Vioxx. We are virtually defenseless.’ Graham revealed that his study showed …

Dr. David Graham FDA Merck U.S. Senate Finance Committee Government Accountability Project regulatory-capture fda pharmaceuticals whistleblower vioxx +2 more

FDA Approves OxyContin with Unsubstantiated Safety Claims

1995-12-20 00:00:00 +0000 UTC | Importance: 9/10

The FDA approved Purdue Pharma’s OxyContin application, including a scientifically unsubstantiated claim that delayed absorption ‘is believed to reduce the abuse liability of a drug.’ This approval occurred without clinical trials to prove the safety claim and marked the beginning …

FDA Purdue Pharma Dr. Curtis Wright Sackler Family regulatory-capture fda pharmaceuticals opioid-crisis revolving-door +1 more

FDA Prescription Drug User Fee Act Creates Financial Dependence on Pharmaceutical Industry

1992-10-29 00:00:00 +0000 UTC | Importance: 9/10

The Prescription Drug User Fee Act (PDUFA) of 1992 fundamentally restructured FDA drug approval financing by creating a direct financial relationship between pharmaceutical companies and regulators. The Act mandated drug companies pay fees to fund FDA drug reviews, which eventually comprised up to …

Food and Drug Administration Pharmaceutical Research and Manufacturers of America (PhRMA) U.S. Congress Pharmaceutical Companies regulatory-capture pharmaceutical-industry fda government-funding institutional-transformation